Latest News in the pharma Industry

Hovione starts clinical trial of its proprietary minocycline sterile ointment to treat a subset of anterior ocular inflammation

25 May 2017

First clinical study using a patent protected minocycline API and formulation developed by Hovione.

IPF patients treated with Ofev vs placebo twice as likely to have improved or stable lung function

25 May 2017

Separate subgroup analysis demonstrates long-term efficacy of Ofev in slowing disease progression is maintained for up to 96 weeks in IPF patients who require dose adjustments to manage adverse events.

New analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids

23 May 2017

New analyses from the FLAME study suggest dual bronchodilator Ultibro Breezhaler provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil counts.

Spiriva Respimat inhalation spray improves breathing for people with asthma regardless of BMI or allergic status

23 May 2017

In all analyses, people experiencing uncontrolled asthma symptoms saw improvements in their breathing by adding Spiriva Respimat to an ICS or combination ICS/LABA.

FDA approves Genentech’s Actemra for giant cell arteritis

22 May 2017

Sixth FDA approval for Actemra since its US launch in 2010,

Catalent and Therachon to advance clinical development of innovative protein therapy for achondroplasia

15 May 2017

Catalent Biologics will use its proprietary GPEx technology to produce different protein variants for Therachon,

Positive results for Lilly's three Phase III studies of galcanezumab for the prevention of migraine

14 May 2017

Genentech to present new data on personalized medicines and cancer immunotherapies

12 May 2017

New pivotal results for Perjeta and Alecensa demonstrating improvement over standards of care.

Avastin as effective as Eylea for treating central retinal vein occlusion

12 May 2017

NIH-funded clinical trial shows use of either drug improved vision and had few side effects.

Merck's Keytruda scores another FDA approval

11 May 2017

FDA approves Keytruda as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression.

Roche's Tecentriq flops during Phase III trial

10 May 2017

IMvigor211 failed to meet its primary endpoint of overall survival (OS) compared with chemotherapy.

Optibrium and Goldfinch Bio sign agreement for StarDrop license

9 May 2017

Goldfinch Bio’s researchers select StarDrop to guide successful drug discovery.